Kornimate/medical-research-clean huggingface dataset:
the impact of lung cancer-derived fibroblasts on mast cells activation

Conditions: Lung Cancer

Summary: in addition to their role in allergic inflammation, mast cells are often found at the site of tumors. they have been attributed both to pro- and anti-tumorigenic roles depending on the tumor type. secretion of mast cell mediators such as histamine, tryptase, fibroblast growth factor (b-fgf), vascular endothelial growth factor (vegf) and interleukin-8 (il-8) can enhance tumor growth and angiogenesis while tnf-a and heparin act as tumor suppressors. the non-small cell lung cancer constitutes the majority of cases of lung cancer. in lung cancer, mast cell numbers correlate with tumor angiogenesis and poor prognosis. in this work, we are interested to determine the factors in lung cancer microenvironment that attribute to mast cell activation. beside the tumor cells themselves, the cancer microenvironment includes other cells such as fibroblasts. the fibroblasts arising from tumor stroma, called cancer-associated fibroblasts (cafs), undergo activation, and have different feature compared to normal fibroblasts (nfs). in this work we are interested to determine whether caf cells derived from lung tumors, together with the lung cancer cells, or microvesicles-derived from these cells, are able to stimulate mast cells to degranulate and/ or to release various cytokines and chemokines. for this propose, during surgery of patients with lung cancer, we will take unnecessary sample from the cancer and from normal area for purification of caf or normal fibroblast cells. those cells will be co-cultured with both lung cancer cell line (a-549) or microvesicles-derived from these cells, and human mast cell line (lad2). supernatants will be collected for determine degranulation and cytokine release from these mast cells.


Eligibility criteria:
inclusion criteria: patient with non small cell lung carcinoma exclusion criteria: none

Keywords: mast cells, lung cancer, cancer associated fibroblasts (caf)
thoracolumbar fascia release on pulmonary function in stroke

Conditions: Stroke; Pulmonary Function; Fascial Manipulation

Summary: this study looks at how thoracolumbar fascia release affects breathing in people who had a stroke. after a stroke, many people have trouble breathing well because their muscles become stiff. we want to see if releasing the thoracolumbar fascia (a big sheet of tissue in the lower back) can help improve lung function. participants will be divided into three groups: control group - receives standard stroke rehabilitation. breathing exercise group - gets standard rehabilitation plus breathing exercises. thoracolumbar fascia release group - gets standard rehabilitation plus thoracolumbar fascia release therapy. we will measure lung function right after a single session to see if this therapy makes breathing easier. our primary outcome is to check if thoracolumbar fascia release improves lung function compared to the other groups. this study hopes to find new ways to help stroke survivors breathe better and feel more comfortable.

this randomized controlled study investigates the immediate effects of thoracolumbar fascia (tlf) release on pulmonary function in stroke patients. post-stroke impairments often lead to respiratory dysfunction due to musculoskeletal restrictions and altered neuromuscular control. given the biomechanical connections between the thoracolumbar fascia and the respiratory system, we hypothesize that tlf release may enhance pulmonary mechanics by improving respiratory functions, in single session. participants randomly assigned into three groups: control group - receives standard post-stroke rehabilitation. respiratory exercise group - undergoes standard rehabilitation combined with structured breathing exercises. tlf release group - receives standard rehabilitation along with thoracolumbar fascia release. the primary outcome measure is the immediate change in spirometric parameters, including forced vital capacity (fvc%), forced expiratory volume in one second (fev₁%), fev₁/fvc (tiffeneu index) and peak expiratory flow (pef%). by evaluating the acute effects of thoracolumbar fascial release on respiratory function, this study aims to explore a potential adjunct therapy for post-stroke pulmonary rehabilitation.

Eligibility criteria:
inclusion criteria: eligible participants were male patients aged 18-65 years, diagnosed with monohemispheric ischemic stroke above the brainstem, confirmed through computed tomography or magnetic resonance imaging and a stroke diagnosis at least six months prior to the study. exclusion criteria: severe cardiorespiratory or neuromuscular disease, tracheostomy, obesity (bmi ≥30 kg/m²), rib cage deformity, cognitive impairment (mini-mental state examination score ≤ 20), and severe dysphagia, aphasia or confusion.

Keywords: myofascial release pulmonary function test spirometry stroke thoracolumbar fascia
registry of acute medical emergencies in brazil

Conditions: Acute Coronary Syndromes; Heart Failure; Pulmonary Edema; Aortic Aneurysm, Familial Thoracic 1; Chest Pain; Pulmonary Embolism; Syncope

Summary: critical patients in emergency room are seriously situations that need quickly diagnosis and treatment. different predictors of prognosis can be related with mortality and morbidity in-hospital and in long-term. in brazil, this kind of registry is not available. the aim of the study is analysis and report data about critical patients in emergency departments over all country, showing demographic, clinical and prognosis data about that in brazil.

this will be a prospective and multicentric data-bank registry. initially, all patients with acute coronary syndromes (acs), acute decompensated heart failure (adhf), warfarin intoxication, acute pulmonary edema, acute aortic dissection, chest pain, pulmonary embolism and syncope will be included. there will be not exclusion criteria. the inclusion criteria will be followed by definition of each illness described in recent guidelines. investigators estimated annually over than 500 cases with acs/chest pain, 300 cases of adhf, 200 cases of aortic dissection, 200 of pulmonary embolism, 200 cases of warfarin intoxication, 100 cases of syncope and 150 of acute pulmonary edema. clinical data, electrocardiographic and echocardiographic findings, laboratory results and prognosis will be related. routine of treatment will be defined by each center. the analysis includes minimum, medium and maximum values. variables will be adjusted according with each diagnosis and all data will be included using the redcap digital data entry. probabilities will be determined by logistic regression and will be considered significate when p \< 0.005. prospectively, investigators will use the cox model to calculate associations.

Eligibility criteria:
inclusion criteria: * all patients with: * acute coronary syndromes (acs) or, * acute decompensated heart failure (adhf) or, * warfarin intoxication or, * acute pulmonary edema or, * acute aortic dissection or, * chest pain or, * pulmonary embolism or * syncope. exclusion criteria: -there will be not exclusion criteria.
fujilam prospective evaluation trial

Conditions: Diagnosis of Tuberculosis in People Living With HIV

Summary: this is a prospective, multicentre cohort study in which the accuracy and the diagnostic yield of the fujilam test will be assessed using a microbiological reference standard, an extended microbiological reference standard and a composite reference standard among inpatient and outpatient people living with hiv (plhiv).


Eligibility criteria:
inclusion criteria: * adult plhiv (≥18 years), irrespective of their cd4 count and antiretroviral therapy (art) status, at risk of having pulmonary and/or extra-pulmonary tb * inpatients: irrespective of tb symptoms * outpatients: at least one of the symptoms suggestive of tb (as defined by who\*) * written informed consent * willingness to have a trial follow-up visit at 2-3 and 6 months after enrolment (e.g. not planning to relocate) exclusion criteria: * current anti-tb treatment \* * any anti-tb treatment within 60 days prior to enrolment * any isoniazid preventive therapy within 6 months prior to enrolment \* patients starting anti-tb treatment at the time of enrolment will not be excluded from the trial provided that all trial specimens are collected before starting the 3rd dose of treatment.

Keywords: tuberculosis, plhiv
a randomized double-blind trial with 6 antipsychotic drugs for schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to compare the efficacy and side effects of 6 commonly used antipsychotic drugs in the treatment of schizophrenia in a chinese population.

the relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. the investigators compared a first-generation antipsychotic, perphenazine or haloperidol, with several newer drugs in a double-blind study. methods: a total of 550 patients with schizophrenia were recruited at 4 chinese sites and randomly assigned to receive perphenazine (16 to 64 mg per day) or haloperidol(6 t0 20mg per day), olanzapine (5 to 20 mg per day), quetiapine (400 to 750 mg per day), aripiprazole (10 to 30 mg per day) or risperidone (2 to 6.0 mg per day) for up to 8 weeks.

Eligibility criteria:
inclusion criteria: * patients' diagnoses is based on the results of the structured clinical interview for dsm (scid) using the criteria of the fourth edition of the diagnostic and statistical manual (dsm-iv), physical exams and routine chemistry, and hematology laboratory tests. attending-level psychiatrists will use a chinese translation of the scid to interview patients and their family members, who are given freedom to ask additional questions if respondents do not understand the standard probes. * patients must meet the following criteria: (1) diagnosis of schizophrenia; (2) duration of illness more than 2 years; (3) between 25 and 60 years of age; and (5) have not received antipsychotic medication for at least 1 month;(6) acute exacerbations of chronic inpatients. * a complete medical history, electroencephalograms and electrocardiogram are obtained, and a physical examination and laboratory tests are performed at study entrance. none of the study participants have abnormal findings on these tests. exclusion criteria: -
a supportive care programme for people with heart failure

Conditions: Heart Failure

Summary: efficient health care systems for the management of chronic diseases in the community may improve clinical outcomes and simultaneously encourage patients to remain healthy. supportive care, may contribute to empower heart failure (hf) patients for self- management and providing them with the follow-up and care based on their needs and values through the hf trajectory. to develop the current program an assessment of the support needs of hf patients' will be undertaken and the investigators will take into consideration of their personal preferences, for instance means of communication and way of exercise as part of the intervention. the present study aspires to evaluate the effectiveness of an individualized supportive care management program in terms of the four different components that comprise supportive care in hf. the objectives of this study are to: 1. determine supportive care needs of hf patients as reported in the literature. 2. explore cypriot patients' identified supportive care needs. 3. to develop and test a self-management supportive care programme for hf patients.


Eligibility criteria:
inclusion criteria * clinical diagnoses with hf (hfpef or hfref), established by a cardiologist * new york heart association classification stages i-iv * diagnosis established for at least 6 months before the start of the intervention period * ability to understand, write and read in greek language exclusion criteria: * refuse to take part in the research * dementia or other severe mental illness * transfer to nursing homes after discharge * difficulty in contacting them by a phone call * patients with chronic degenerative diseases (alzheimer, cancer, etc)

Keywords: heart failure supportive care management programme person-centered care
a study of famitinib in combination with hs-10296 in patients with egfr-mutant nsclc

Conditions: EGFR-mutant Non-Small Cell Lung Cancer

Summary: the study is being conducted to evaluate the efficacy, safety and tolerability of famitinib combined with hs-10296 in subjects with advanced egfr-mutant nsclc.


Eligibility criteria:
inclusion criteria: * subject's written informed consent obtained prior to any process, sampling, or analysis related to the study. * male or female, no less than 18 years old. * confirmed as nsclc by histology or cytology. * locally advanced or metastatic nsclc and not suitable for radical surgery or radiotherapy. * have not received egfr tyrosine kinase inhibitor (tki) therapy. * at least one baseline tumor lesion. * can swallow pills normally. * eastern cooperative oncology group (ecog) performance status 0\~1 points, expected survival≥12 weeks. * adequate organ function. exclusion criteria: * clinically symptomatic central nervous system metastases. * ascites, pleural effusion or pericardial effusion with clinical symptoms. * other malignant tumors in the past 5 years or at the same time. * high blood pressure which are not well controlled. * heart disease that are not well controlled. * coagulation dysfunction, bleeding tendency or receiving thrombolysis or anticoagulant therapy. * history of bleeding. * known hereditary or acquired bleeding and thrombophilia. * any serious or uncontrolled ocular lesion. * interstitial lung disease or non-infectious pneumonia treated with corticosteroids. * congenital or acquired immunodeficiency. * other factors that may affect the results of the study or cause the study to be terminated midway.
efficacy and safety of aripiprazole in patients with schizophrenia or bipolar disorder

Conditions: Schizophrenia; Bipolar Disorder

Summary: this is a multicenter,open-label,prospective study of aripiprazole use in patients with schizophrenia and bipolar disorder.

this is a multicenter,open-label,prospective study of aripiprazole use in patients with schizophrenia and bipolar disorder. qualified schizophrenia patients will be enrolled to an 12-week treatment phase of aripiprazole by physician's assessment. qualified bipolar disorder patients will be enrolled to an 8-week treatment phase of aripiprazole by physician's assessment. this study will be continued for 6 years. the final report of aripiprazole pms will be submitted to kfda on december 28, 2009.

Eligibility criteria:
inclusion criteria: * patient with a schizophrenia or schizoaffective disorder or bipolar disorder according to dsm-iv criteria * age: more than 18 years of age exclusion criteria: * unqualified patients judged by study investigator(s)

Keywords: aripiprazole schizophrenia bipolar disorder
allogeneic mesenchymal stem cells transplantation for systemic sclerosis (ssc)

Conditions: Systemic Sclerosis; Mesenchymal Stem Cells

Summary: this study will explore safety and efficacy of allogeneic mesenchymal stem cells transplantation (msct) to treat patients with diagnosis of systemic sclerosis(ssc) who have been resistant to multiple standard treatments. the underlying hypothesis is that the ssc condition is caused by an abnormal immune homeostasis that can be restored by msct.

* to test a new approach using allogeneic derived mesenchymal stem cell based therapy (msct) to treat refractory ssc * to determine the disease-free survival in ssc patients treated with msct * to assess adverse events of allogeneic msc transplantation * to assess the association of remission for organ function, clinical score and ssc serology levels at baseline with disease-free survival

Eligibility criteria:
inclusion criteria: * all patients fulfilled the american college of rheumatology (former american rheumatism association - ara) for ssc * rapidly progressive disease \ 25 mm/first h and/or hb \<11 g/dl, not explained by other causes than active ssc * lung involvement: with a vital capacity (vc) or dlco below 70% predicted, or a mean pulmonary artery pressure (pap) above 40 mmhg (measured by echocardiography) * digestive tract involvement: with serum albumin ,25 g/l or weight loss exceeding 10% body weight in the preceding year * kidney involvement: with 24-h urinary protein above 0.5 g or serum creatinine above 120 mmol/l exclusion criteria: * uncontrolled arrhythmia, echocardiographic left ventricular ejection fraction (lvef) \ 50 mmhg, dlco\<45% of predicted * creatinine clearance \<20 ml/min * platelets\<80 000/mm3, haemorrhagic cystitis * (4) hiv or htlv1 seropositivity, malignancy, pregnancy, a cardiac or vascular prosthesis, and no vascular access

Keywords: systemic sclerosis mesenchymal stem cells transplantation
evaluate the use of plastic bags in preventing and treating hypothermia in neonates

Conditions: Hypothermia, Newborn

Summary: the overall hypothesis is that placing infants 1000-2500 grams in plastic bags when compared to routine care will reduce the risk of hypothermia (\ 37.5 degrees c).

prevention after consent, infants with estimated gestational age between 26-36.6 weeks or with expected birth weight 1000-2500 grams will be randomized to resuscitation per standard protocol or to resuscitation per standard protocol and plastic bag. the intervention group will be placed into a plastic bag covering the body and back and top of head (excluding face) prior to drying the body's surface. resuscitation efforts continue per standard of care. the infant will remain in the bag through the admission process until his/her axillary temp is in the range of 36.5- 37.5 degrees celsius. at this time, the bag will be discontinued and discarded. standard temperature control will be continued per nursery standard. skin-to-skin contact between mother and baby is not excluded; however, the infant will remain in the plastic bag. infant's axillary temperature will be measured per nursery standard after discontinuation of plastic bag. the control group will receive standard of care thermoregulation. secondary measures (i.e. blood pressures, glucose levels, weight gain, observation for respiratory distress syndrome, bronchopulmonary dysplasia, pneumothorax, sepsis, seizures, intraventricular hemorrhage, necrotizing enterocolitis, pulmonary hemorrhage, and death) will be recorded in both groups.

Eligibility criteria:
inclusion criteria: * estimated gestational age 26-36.6 weeks or expected birth weight 1000-2500 grams. * delivery in the hospital. exclusion criteria: * abdominal wall defect or myelomeningocele. * major congenital anomaly. * blistering skin disorder.

Keywords: hypothermia newborn resuscitation plastic bag
slotted hole versus fixed hole c-tek

Conditions: Herniated Disc; Radiculopathy; Spondylolysis

Summary: the purpose of this study is to compare the fusion rates between the ebi, llc c-tek™ anterior cervical plate, slotted hole design versus the fixed hole design.

this study's purpose is to compare the fusion rates between the ebi, llc c-tek™ anterior cervical plate, slotted hole design versus the fixed hole design

Eligibility criteria:
inclusion criteria: 1. radiographic evidence of compressed cervical roots or cord by either ossified bony elements or herniated nucleus pulposus. 2. symptomatic radiculopathy appropriate to compressed nerve root. 3. cervical spondylosis as evidenced by reactive changes in the vertebral bodies about the interspace, and may be associated with chronic discopathy. 4. primary anterior cervical spinal fusion (acdf) performed using an anterior cervical plate and either a discectomy (smith-robinson technique) or a corpectomy. 5. adult male or female, 18 to 75 years of age. 6. the subject or his/her legal guardian is willing to consent to participate in this study. 7. the subject will be available for follow-up for a minimum of 24 months. exclusion criteria: 1. traumatic cervical injury. 2. posterior augmentation or revision fusion. 3. cervical fusion involving c1 and c2 vertebrae. 4. cervical fusion involving more than three levels. 5. previous spine surgery at the same levels as those that will be fixed with the c-tek plate. 6. systemic conditions: spondylitis, paget's disease, rheumatoid arthritis, infection within two weeks before surgery, cancer, renal disease or insufficiency with creatinine level above 2, chronic use of steroids or other conditions that may affect bone metabolism 7. subjects who are pregnant, nursing or plan to be pregnant within the next 24 months. 8. mental or physical conditions that may preclude compliance with physician instruction or the study protocol. 9. subjects who require non-steroidal medications chronically for other conditions. 10. subject declines to cooperate with the follow-up schedule. 11. subject or legal guardian refuses or is unable to sign the informed consent.
atorvastatin in pulmonary hypertension

Conditions: Hypertension, Pulmonary

Summary: clinical effect and tolerability of atorvastatin versus placebo in patients with pulmonary hypertension: double-blinded, randomised, prospective phase ii study for 6 months with adjusted doses of atorvastatin

pah is characterized by dyspnea, fatigue, and lower extremity edema as a result of heart failure. several research have proved that inflammation may participate in the pathogenesis of pah. as atorvastatin inhibits inflammation and has beneficial effects on blood vessels in other types of cardiovascular disease. therefore, atorvastatin may similarly benefit patients with pah. experimental data suggest that statins attenuates pulmonary hypertension in animal experiments. in addition, non-controlled clinical studies suggest that atorvastatin is effective and safe in patients with pulmonary hypertension. participants in this study will be randomly assigned to receive 6 months of daily placebo tablets or daily atorvastatin in a double-blind fashion. the study will compare the safety and efficacy of placebo and atorvastatin.

Eligibility criteria:
inclusion criteria: * able to understand and willing to sign the informed consent form * \ =18years old * diagnosis of pulmonary arterial hypertension (mean pulmonary artery pressure greater than 25 mm hg at rest with a pulmonary capillary wedge pressure less than 15 mm hg )that is a) idiopathic, b) familial, or c) associated with connective-tissue disease, d)congenital systemic-to-pulmonary shunt occurring after surgical/interventional repair that had been performed at least five years previously or in the absence of indications for surgery/intervention treatment e) chronic thromboembolism pah in the absence of indications for surgery * patients in who functional class ii to iii * vasodilator testing nonresponders * baseline six-minute walking distance between 100 and 460 m exclusion criteria: * pah related to other etiologies (groups 2, 3 and 5 pulmonary hypertension) * a forced expiratory volume in one second/ forced vital capacity bellow 50% or a total lung capacity of less than 60 percent predicted value * a 6-minute walk distance of less than 100 or more than 460 m * a positive acute vasodilator response * current treatment with calcium-channel blockers or specific therapy (endothelin receptor antagonist, phosphodiesterase-5 inhibitor, or prostacyclin) * inability to perform 6-minute walk test * serum transaminase level three times above the upper limit of normal * creatine kinase level five times above the upper limit of normal * previously diagnosed heart disease such as serious cardiac arrhythmias, unstable angina pectoris, myocardial infarction * history of transient ischemia attack or stroke within three months * bleeding disorder * positive pregnancy test or breastfeeding practice * history or suspicion of inability to cooperate

Keywords: pulmonary arterial hypertension